Medindia

X

Sangart, Inc. Announces Key Executive Appointments and Company Restructuring

Thursday, January 8, 2009 General News J E 4
Advertisement
Business Units Refocused on Additional Clinical Studies Planned for Hemospan(R)



SAN DIEGO, Jan. 7 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen-therapeutic agents, today announced a company restructuring that includes the addition of three key leadership positions and a significant reduction in work force, primarily in the product manufacturing area. This restructuring reduces the company's burn rate and refocuses Sangart's business units on pursuing further clinical trials for its lead product, Hemospan(R).



"Sangart remains committed to developing a safe and effective oxygen-therapeutic agent," said Brian O'Callaghan, President and Chief Executive Officer of Sangart. "Our recent successful Phase III clinical studies of Hemospan demonstrated very encouraging efficacy results for the prevention and treatment of hypotension in hip replacement procedures. These trials provide a platform from which to conduct the pivotal clinical studies that will be necessary to establish the clinical benefit of treating patients with Hemospan. The appointment of key executives and the decision to reduce our workforce, which was difficult but necessary, will enable us to focus our resources on these upcoming clinical trials."



As part of the restructuring, Sangart announced appointments for three new leadership positions:









About Sangart

Sangart, Inc. is a privately held biopharmaceutical company focused on being the global scientific, clinical and commercial leader in oxygen-therapeutic agents, providing innovative products to patients in need. Sangart was founded based on technologies developed during more than two decades of research into the mechanisms of oxygen transport by cell-free hemoglobin solutions at the Letterman Army Institute of Research and University of California at San Diego. The discoveries arising from this research on the effective action of oxygen therapeutics have been patented and published in numerous scientific articles and form the basis for Sangart's technologies.



About Hemospan(R)

Sangart's lead product candidate, Hemospan(R) is an oxygen therapeutic product that is created using unique polyethylene glycol conjugation with human hemoglobin. Hemospan(R) was specifically designed to the optimal molecular size, viscosity, oxygen affinity and diffusion potential to target oxygen delivery to tissues at risk of oxygen deprivation based on experiments with artificial capillaries and in several different animal models. Extensive research and testing demonstrates that this approach optimizes oxygen delivery in the microcirculation while minimizing the side effects that plagued earlier generation products.



To learn more about Sangart or Hemospan, please visit www.sangart.com.





-- Howard Levy MD, PhD, Chief Scientific Officer - Dr. Levy will assume overall responsibility for preclinical, clinical research, and research and development for Hemospan. A critical care and pulmonary physician, Dr. Levy brings more than 20 years of experience both serving as a principal investigator at research institutions as well as leading clinical study development teams for pharmaceutical companies. Prior to Sangart, he was responsible for clinical research of the hemostasis platform at Novo Nordisk, Inc.

SOURCE Sangart, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Press Ganey Acquires PatientFlow Technology
S
The Non-Profits Medical Tourism Association (MTA),...